Prognostic Factors and Multidisciplinary Postoperative Chemoradiotherapy for Clinical T4a Tongue Cancer.

abstract：OBJECTIVE:Our aim is to assess the clinicopathological significance of E-cadherin and beta-catenin expression, as well as their association with apoptosis in gallbladder cancers. METHODS:The expression of E-cadherin and beta-catenin proteins was examined in 4 biliary tract cancer cell lines and 49 gallbladder cancer s...

journal_title：Oncology

authors： Hirata K,Ajiki T,Okazaki T,Horiuchi H,Fujita T,Kuroda Y

更新日期：2006-01-01 00:00:00

abstract：OBJECTIVES:Surgery has traditionally been the treatment of choice for patients with potentially resectable esophageal carcinoma. Recently, however, definitive chemoradiotherapy (CRT) has been suggested as a preferred treatment modality. In this study, CRT results with or without surgery are compared. METHODS:A total o...

journal_title：Oncology

authors： Salek R,Tabrizi FV,Bezenjani SE,Saedi HS,Ashkiki MH,Hosainzadeh SM,Mohtashami S

更新日期：2011-01-01 00:00:00

abstract：OBJECTIVE:In order to improve the prognosis of pancreatic cancer patients, it is crucial to explore novel tools for its early diagnosis. Here, we attempted to screen serum biomarkers to distinguish pancreatic cancer from non-cancer individuals. METHODS:47 serum samples from pancreatic cancer patients, 39 of whom had s...

journal_title：Oncology

authors： Yu Y,Chen S,Wang LS,Chen WL,Guo WJ,Yan H,Zhang WH,Peng CH,Zhang SD,Li HW,Chen GQ

更新日期：2005-01-01 00:00:00

abstract：:Thirty-eight patients with metastatic renal-cell carcinoma (RCC) and 1 patient with a second primary RCC were treated with coumarin and cimetidine. Patients received 400 mg cimetidine p.o. daily and after 1 week 100 mg coumarin p.o. daily in addition until tumour progression. Two complete remission (30 and 50+ months)...

journal_title：Oncology

authors： Kokron O,Maca S,Gasser G,Schmidt PR

更新日期：1991-01-01 00:00:00

abstract：:To improve the ability of an in vitro drug sensitivity test to predict in vivo effects, we applied a drug concentration that was pharmacokinetically equivalent to plasma levels and collagen gel droplet-embedded culture with a high cloning efficiency. We reported that the cell-killing effect of cell cycle phase-nonspec...

journal_title：Oncology

authors： Inaba M,Tashiro T,Sato S,Ohnishi Y,Tanisaka K,Kobayashi H,Koezuka M

更新日期：1996-05-01 00:00:00

abstract：:The activities of established and experimental antitumor drugs were tested against the BRO and MeWo human melanomas transplanted in the subrenal capsule of phenotypically immunocompetent (CBA x C57BL/6)F1 mice. Immunosuppression was achieved with preliminary whole-body radiation, and cytological examination showed tha...

journal_title：Oncology

authors： Ryabkova VI,Lockshin A,Strukov IG,Sokolova VK

更新日期：1994-11-01 00:00:00

abstract：:A total of 103 patients with lung cancer was treated with CCNU 130 mg/m2 orally every 6 weeks; 65 patients survived at least 6 weeks. Partial responses occurred in 7 patients. Leukopenia, thrombocytopenia, and nausea were frequent toxic effects. CCNU has slight efficacy in advanced lung cancer. No increase in survival...

journal_title：Oncology

authors： Stolinsky DC,Bull FE,Pajak TF,Bateman JR

更新日期：1975-01-01 00:00:00

abstract：OBJECTIVE:Expression of vascular endothelial growth factor (VEGF)-D by tumors is associated with metastasis to lymph nodes in mice. However, there are few reports concerning the clinical significance of VEGF-D protein in human carcinoma. METHODS:After confirming production of VEGF-D by eight colorectal carcinoma cell ...

journal_title：Oncology

authors： Funaki H,Nishimura G,Harada S,Ninomiya I,Terada I,Fushida S,Tani T,Fujimura T,Kayahara M,Shimizu K,Ohta T,Miwa K

更新日期：2003-01-01 00:00:00

abstract：:The treatment of metastatic renal cell carcinoma (MRCC) has evolved from being predominantly cytokine-based to being grounded in the use of drugs targeting vascular endothelial growth factor, platelet-derived growth factor and mammalian target of rapamycin (mTOR) pathways. New agents including the small-molecule targe...

journal_title：Oncology

authors： Di Lorenzo G,Scagliarini S,Di Napoli M,Scognamiglio F,Rizzo M,Carteni' G

更新日期：2009-01-01 00:00:00

abstract：:This paper presents clinical observations on 130 patients with carcinoma of the pancreas, including 19 with periampullary cancer, the first large study of this disease in Iraq. All of the patients were admitted to the First (one of three) Surgical Unit of the University of Baghdad Teaching Hospital (the Medical City) ...

journal_title：Oncology

authors： Al-Bahrani ZR,Al-Mondhiry HA,Al-Saleem T

更新日期：1982-01-01 00:00:00

abstract：:Empiric clinical trials have revealed new mechanisms by which hormonal therapies may exert their antitumor effects. Initial studies using escalated doses of agents like toremifene and megestrol acetate have yielded interesting results, showing responses in hormone-receptor-negative patients and in patients progressing...

journal_title：Oncology

authors： Abrams JS,Gutheil J,Aisner J

更新日期：1992-01-01 00:00:00

abstract：:Tumor infiltrating lymphocytes induced by radiotherapy were analyzed by the biotin-avidin-horseradish peroxidase method. At the early dose of 4 Gy (400 rad) of irradiation (2 Gy X 2), remarkable infiltration of lymphocytes was observed surrounding cancer cells. This infiltration was mainly composed of Leu-3a+3b-positi...

journal_title：Oncology

authors： Ogawa Y,Maeda T,Seguchi H,Hamada F,Inomata T,Yoshida S,Kishimoto S,Saito H

更新日期：1988-01-01 00:00:00

abstract：:Surgical resection, transarterial chemoembolization, percutaneous ethanol injection therapy, radiofrequency ablation, and orthotopic liver transplantation are generally accepted treatment modalities in hepatocellular carcinoma, but there has been no standard therapy for patients at the advanced stage. Several combinat...

journal_title：Oncology

authors： Lee HC

更新日期：2008-01-01 00:00:00

abstract：BACKGROUND:It is unclear for whom new anti-human epidermal growth factor receptor 2 (anti-HER2) agents, such as pertuzumab and T-DM1, should be considered. We investigated prognostic factors before neoadjuvant chemotherapy (NAC) among HER2-positive invasive breast cancer patients and those after NAC among patients who ...

journal_title：Oncology

authors： Fujita N,Enomoto Y,Inakami K,Yanagisawa T,Iguchi C,Aono T,Nomura T,Yamamoto H,Kasugai T,Shiba E

更新日期：2020-01-01 00:00:00

abstract：OBJECTIVES:Angiogenesis plays an important role in ovarian cancer. The interaction of platelet-derived growth factor receptor-beta (PDGFR-β) with vascular endothelial growth factor (VEGF) in the process of angiogenesis may represent an essential feature in the progression of the disease. METHODS:Patients with epitheli...

journal_title：Oncology

authors： Mathey S,Graeser MK,Zu Eulenburg C,Woelber L,Trillsch F,Jaenicke F,Müller V,Milde-Langosch K,Mahner S

更新日期：2013-01-01 00:00:00

abstract：:Cisplatin is among the most active agents available for the therapy of non-small cell lung cancer (NSCLC). Its congener, carboplatin, has been the focus of intense clinical trials over the last several years because of its improved therapeutic index. Results from randomized trials have shown that carboplatin is active...

journal_title：Oncology

authors： Comis RL

更新日期：1993-11-01 00:00:00

abstract：:23 patients received cis-platinum, doxorubicin and cyclophosphamide for gynecologic malignancy between December 1, 1980 and December 1, 1982. Each patient was randomized with each course of chemotherapy to receive intravenous droperidol or the combination of promethazine and chlorpromazine rectal suppositories as an a...

journal_title：Oncology

authors： Roberts WS,Wisniewski BJ,Cavanagh D,Marsden DE

更新日期：1985-01-01 00:00:00

abstract：:Sorafenib, an oral multikinase inhibitor, has demonstrated clinical efficacy in patients with advanced hepatocellular carcinoma (HCC). However, in the SHARP trial (Sorafenib HCC Assessment Randomized Protocol trial) and the Asia-Pacific trial (conducted in the Asia-Pacific region), no cases of complete response (CR) w...

journal_title：Oncology

authors： Inuzuka T,Nishikawa H,Sekikawa A,Takeda H,Henmi S,Sakamoto A,Saito S,Kita R,Kimura T,Osaki Y,Kudo M

更新日期：2011-01-01 00:00:00

abstract：:The effect of the differentiation-inducing agent dimethylsulfoxide (DMSO) on the protein composition of hepatic tumor cells was evaluated using the BW77-1 line of murine hepatoma cells previously determined to be DMSO-inducible for enhanced liver function. DMSO-mediated suppression of BW77-1 proliferation was accompan...

journal_title：Oncology

authors： Higgins PJ

更新日期：1984-01-01 00:00:00

abstract：OBJECTIVE:To assess the efficacy of percutaneous cementoplasty for painful bone metastasis from hepatocellular carcinoma (HCC). METHODS:Cementoplasty was performed for 22 metastatic bone tumors in 13 patients. All patients had intractable pain and were diagnosed as metastatic bone tumor from HCC. The ostyneedle was in...

journal_title：Oncology

authors： Kodama H,Aikata H,Uka K,Takaki S,Mori N,Waki K,Jeong SC,Kawakami Y,Shirakawa H,Takahashi S,Toyota N,Ito K,Chayama K

更新日期：2007-01-01 00:00:00

abstract：PURPOSE:Cancer-related fatigue is a common complaint during cancer treatment and is often associated with cognitive impairment. This study examined cognitive deficits that were associated with fatigue symptoms during external-beam radiation therapy (EBRT) in men with localized prostate cancer. METHODS:A total of 36 pa...

journal_title：Oncology

authors： Feng LR,Espina A,Saligan LN

更新日期：2018-01-01 00:00:00

abstract：:In 29 patients (48 courses of chemotherapy), a randomized double-blind crossover study was undertaken to establish the antiemetic effectiveness of a combination of metoclopramide at a moderately high dose (5 mg/kg body weight) with 1 g methylprednisolone (treatment A) as compared with metoclopramide monotherapy (5 mg/...

journal_title：Oncology

authors： Ell C,König HJ,Brockmann P,Domschke S,Domschke W

更新日期：1985-01-01 00:00:00

abstract：INTRODUCTION:Breast cancer is one of the leading causes of death worldwide and is the result of dysregulation of various signaling pathways in mammary epithelial cells. The mortality rate in patients suffering from breast cancer is high because the tumor cells have a prominent invasive capacity towards the surrounding ...

journal_title：Oncology

authors： González-González L,González-Ramírez R,Flores A,Avelino-Cruz JE,Felix R,Monjaraz E

更新日期：2019-01-01 00:00:00

abstract：INTRODUCTION:Carcinoma of the biliary system is a rare tumor entity, and patients with advanced disease face a dismal prognosis. Because of the absence of standard chemotherapy for advanced biliary carcinoma, we have performed two consecutive studies to evaluate the clinical potential of 5-fluorouracil, leucovorin and ...

journal_title：Oncology

authors： Raderer M,Hejna MH,Valencak JB,Kornek GV,Weinländer GS,Bareck E,Lenauer J,Brodowicz T,Lang F,Scheithauer W

更新日期：1999-04-01 00:00:00

abstract：INTRODUCTION:Because the frequency of bile duct invasion in hepatocellular carcinoma (HCC) patients is very rare, there is limited clinical evidence to demonstrate the outcomes of systemic therapy in HCC with bile duct invasion. OBJECTIVE:Our aim was to clarify the efficacy and safety of sorafenib treatment in patient...

journal_title：Oncology

authors： Tanaka T,Kuzuya T,Ishigami M,Ito T,Ishizu Y,Honda T,Ishikawa T,Fujishiro M

更新日期：2020-01-01 00:00:00

abstract：BACKGROUND:Radioimmunotherapy (RIT) is effective in treating relapsed/refractory follicular lymphoma (FL), with durable remissions in first-line consolidation. We hypothesized that RIT with ibritumomab tiuxetan (Zevalin®) would result in durable remissions by eliminating minimal residual disease after cytoreduction. M...

journal_title：Oncology

authors： Puvvada SD,Guillén-Rodríguez JM,Yan J,Inclán L,Heard K,Rivera XI,Anwer F,Mahadevan D,Schatz JH,Persky DO

更新日期：2018-01-01 00:00:00

abstract：:C57BL/6 mice with progressive B-16 melanoma develop a generalized immunosuppression, as measured by their lack of response to SRBC in vivo and in vitro. The severity of immunosuppression increases with the progress of the tumor, and is due to the generation of an antigen-nonspecific suppressor cell. Suppressor cells w...

journal_title：Oncology

authors： Stelzer GT,Wallace JH

更新日期：1980-01-01 00:00:00

abstract：OBJECTIVE:We performed a pilot study to evaluate the effect of the high-dose gemcitabine-cisplatin combination in a brief weekly regimen in the treatment of primary refractory diffuse large cell lymphoma with high or high-intermediate clinical risk. METHODS:Thirty patients refractory to first-line anthracycline-based ...

journal_title：Oncology

authors： Avilés A,Neri N,Huerta-Guzmán J,Fernández R

更新日期：2004-01-01 00:00:00

abstract：BACKGROUND:Osteosarcoma is a rare malignancy, and patients with this disease benefit from adjuvant chemotherapy. While cisplatin, anthracyclines and ifosfamide are the most commonly used agents in the treatment of osteosarcoma, a search for the best combination with higher efficacy and minimal toxicity continues. We pl...

journal_title：Oncology

authors： Basaran M,Bavbek ES,Saglam S,Eralp L,Sakar B,Atalar AC,Bilgic B,Ozger H,Onat H

更新日期：2007-01-01 00:00:00

abstract：:Breast conservation treatment followed, if useful, by adjuvant therapy is the treatment of choice in early breast cancer. Late cosmetic outcome and toxicity are important in comparing conservative treatment to mastectomy. We reviewed the records of 225 patients treated from 1981 to 1988 with a median follow-up of 74 m...

journal_title：Oncology

authors： Amichetti M,Busana L,Caffo O

更新日期：1995-05-01 00:00:00